GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frontage Holdings Corp (HKSE:01521) » Definitions » COGS-to-Revenue

Frontage Holdings (HKSE:01521) COGS-to-Revenue : 0.72 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frontage Holdings COGS-to-Revenue?

Frontage Holdings's Cost of Goods Sold for the six months ended in Dec. 2024 was HK$711 Mil. Its Revenue for the six months ended in Dec. 2024 was HK$983 Mil.

Frontage Holdings's COGS to Revenue for the six months ended in Dec. 2024 was 0.72.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Frontage Holdings's Gross Margin % for the six months ended in Dec. 2024 was 27.66%.


Frontage Holdings COGS-to-Revenue Historical Data

The historical data trend for Frontage Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frontage Holdings COGS-to-Revenue Chart

Frontage Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.67 0.64 0.64 0.70 0.73

Frontage Holdings Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 0.70 0.70 0.73 0.72

Frontage Holdings COGS-to-Revenue Calculation

Frontage Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1438.825 / 1981.494
=0.73

Frontage Holdings's COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=710.979 / 982.807
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frontage Holdings  (HKSE:01521) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Frontage Holdings's Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 710.979 / 982.807
=27.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Frontage Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Frontage Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Frontage Holdings Business Description

Traded in Other Exchanges
N/A
Address
700 Pennsylvania Drive, Exton, PA, USA, 19341
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
Executives
Li Song 2101 Beneficial owner
Hongkong Tigermed Co., Limited
Hang Zhou Tai Ge Yi Yao Ke Ji Gu Fen You Xian Gong Si 2101 Beneficial owner
Kabouter Management Llc 2102 Investment manager
Hangzhou Tigermed Consulting Co., Ltd.

Frontage Holdings Headlines

No Headlines